Effects of Systemic Enzyme Supplements on Symptoms and Quality of Life in Patients with Pulmonary Fibrosis—A Pilot Study

Current FDA-approved antifibrotic treatments for Idiopathic Pulmonary Fibrosis slow down disease progression but have little impact on symptoms or quality of life in patients. This study was conducted to evaluate the effects of systemic enzymes in relieving symptoms associated with PF and improving...

Descripción completa

Detalles Bibliográficos
Autor principal: Shah, Neha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8624573/
https://www.ncbi.nlm.nih.gov/pubmed/34822365
http://dx.doi.org/10.3390/medicines8110068

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8624573/
https://www.ncbi.nlm.nih.gov/pubmed/34822365
http://dx.doi.org/10.3390/medicines8110068

Ejemplares similares